Upfront Therapies and Downstream Effects: Navigating Late Effects in Childhood Cancer Survivors in the Current Era. Curr Oncol Rep 2019 Nov 25;21(12):104
Date
11/27/2019Pubmed ID
31768799DOI
10.1007/s11912-019-0861-8Scopus ID
2-s2.0-85075563534 (requires institutional sign-in at Scopus site) 6 CitationsAbstract
PURPOSE OF REVIEW: As survival rates of those diagnosed with childhood cancer improve over time, the number of long-term survivors continues to grow. Advances have not only been made in the upfront treatment of childhood cancer, but also in the identification and treatment of late complications that may arise as a result of the chemotherapy, radiotherapy, or surgical interventions required to provide a cure.
RECENT FINDINGS: As new therapies emerge that are often more targeted to cancerous cells while sparing healthy tissues, the hope is that cure can be achieved without the same long-term side effects for survivors. However, much is unknown regarding how these novel interventions will impact patients in the years to come. It is critical that we continue to follow patients treated with new modalities in order to identify and treat the long-term complications that may arise in future childhood cancer survivors.
Author List
Phelan R, Eissa H, Becktell K, Bhatt N, Kudek M, Nuechterlein B, Pommert L, Tanaka R, Baker KSAuthors
Kerri Becktell MD Associate Professor in the Pediatrics department at Medical College of WisconsinMatthew Kudek MD Assistant Professor in the Pediatrics department at Medical College of Wisconsin
Rachel A. Phelan MPH, MD Professor in the Pediatrics department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
Cancer SurvivorsCardiovascular Diseases
Child
Cognition Disorders
Disease Progression
Endocrine System Diseases
Humans
Neoplasms
Risk Factors
Survival Rate
